Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02609100
Other study ID # 201507101
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date November 2015
Est. completion date December 6, 2016

Study information

Verified date June 2018
Source Washington University School of Medicine
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Acute gastrointestinal bleeding is a common medical problem. When patients with gastrointestinal bleeding present with melena (dark, tarry stool) the blood loss is usually originating in the upper gastrointestinal tract (esophagus, stomach or duodenum) and first step in evaluating the patient is an upper endoscopy; which allows direct visualization of the esophagus, stomach and duodenum. However, the cause of bleeding is located in the small bowel or colon in 20-30% of patients who present with melena. Traditionally colonoscopy has been the next test preformed if upper endoscopy does not identify the cause of melena/ gastrointestinal bleeding, however less than 25% of patients who present with melena have bleeding originating in the colon, and the remainder of patients have bleeding originating in the small intestine, which can only be fully evaluated with video capsule endoscopy (a pill camera which is swallowed and takes pictures while it travels thought the small bowel and colon). Currently patients only undergo video capsule endoscopy if colonoscopy does not identify the cause of bleeding. The investigators are preforming a randomized study which seeks to determine if colonoscopy or video capsule endoscopy is a better way to identify the cause of gastrointestinal bleeding in patients who present with melena and have normal findings on upper endoscopy. To do this the investigators will enroll patients who present with melena prior to their upper endoscopy and if the cause of bleeding is not identified at that time patients will be randomized to video capsule endoscopy (with the capsule being placed into the small bowel during the upper endoscopy) or next day colonoscopy.


Recruitment information / eligibility

Status Terminated
Enrollment 4
Est. completion date December 6, 2016
Est. primary completion date December 6, 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

• Inpatients >18 years of age presenting with lower gastrointestinal bleeding and have melenic stool

Exclusion Criteria:

- Unable to provide written informed consent

- A probable bleeding source is identified on upper endoscopy

- Pregnancy or lactation

- Swallowing Disorder

- Unable to tolerate sedation or anesthesia due to medical co-morbidities

- Uncorrected coagulopathy (platelet count <50,000, INR> 2, PTT> 2x upper limit of normal)

- Known or suspected gastrointestinal obstruction or stricture

- Cardiac pacemaker or other implanted electromedical device

- Contraindication to bowel preparation

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Video Capsule Endoscopy
Video Capsule Endoscopy allows for imaging of the small intestine between the distant duodeno-jejunal junction, which is beyond the reach of upper GI endoscopy and the terminal ileum and is similarly beyond the reach of colonoscopy. It is of greatest use in identifying points of bleeding and ulcers.
Colonoscopy
The colonoscopy helps find ulcers, tumors, and areas of inflammation or bleeding in the large intestine.
Device:
1.0 X 2.5 cm 'pill' containing a camera


Locations

Country Name City State
United States Center for Advanced Medicine Saint Louis Missouri

Sponsors (1)

Lead Sponsor Collaborator
Washington University School of Medicine

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Clinically Significant Findings Defined as Lesions Considered to Have a High Potential for Bleeding to Participants With no Significant Findings From Video Capsule Endoscopy Video Capsule Endoscopy identifies clinically significant lesions defined as lesions considered to have high potential for bleeding, such as a large ulceration, tumor or typical angiomata Up to twenty four hours
Primary Number of Participants With Clinically Significant Findings Defined as Lesions Considered to Have a High Potential for Bleeding to Participants With no Significant Findings From Colonoscopy Colonoscopy identifies clinically significant lesions defined as lesions considered to have high potential for bleeding, such as a large ulceration, tumor or typical angiomata Up to one hour
Secondary Therapeutic Yield of Video Capsule Endoscopy Therapeutic yield of video capsule endoscopy is defined as the proportion of endoscopies leading to a therapeutic intervention. Up to 7 days
Secondary Therapeutic Yield of Colonoscopy Therapeutic yield of colonoscopy is defined as the proportion of endoscopies leading to a therapeutic intervention. Up to 7 days
Secondary Number of Blood Units Transfused Number of blood units transfused measured in units of packed red blood cells Up to 60 days
Secondary Number of Diagnostic Studies Performed for Evaluation of Gastrointestinal Bleeding Includes repeat endoscopies or imaging Up to 60 days
Secondary Duration of Hospital Stay The duration of hospital stay will be recorded in number of days Up to 60 days
Secondary Procedure Related Adverse Events Adverse events related to the video capsule endoscopy and colonoscopy will be recorded Up to 60 days
See also
  Status Clinical Trial Phase
Completed NCT02903017 - Local Administration of Tranexamic Acid in Upper Gastrointestinal Hemorrhage Phase 4
Recruiting NCT02514304 - Study of the Risk Factors and Outcomes After Gastrointestinal Bleeding
Completed NCT02384122 - Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias Phase 3
Completed NCT01477320 - Enteral Nutrition as Stress Ulcer Prophylaxis in Critically Ill Patients. N/A
Not yet recruiting NCT01549418 - The Risk of Bleeding After Removal of Large Colorectal Polyps in Patients Taking Aspirin Phase 4
Completed NCT02105532 - Transfusion in Gastrointestinal Bleeding Phase 2/Phase 3
Recruiting NCT05226221 - Gastrointestinal Emergency Surgery: Evaluation of Morbidity and Mortality
Active, not recruiting NCT02874326 - Octreotide in Patients With GI Bleeding Due to Rendu-Osler-Weber Phase 2
Completed NCT02928939 - Therapeutic Conflicts and Multimorbidity
Withdrawn NCT01215058 - Gastroprotective Agent Compliance in Patients at Risk Suffering From a Gastrointestinal(GI) Ulcer N/A
Completed NCT01029626 - Glasgow-Blatschford Score Validation in Digestive Hemorrhage N/A
Completed NCT00251979 - A Study to Prevent Rebleeding After Initial Successful Primary Endoscopic Haemostasis of a Bleeding Peptic Ulcer Phase 3
Completed NCT02991612 - Rifaximin in Patients With Gastroesophageal Variceal Bleeding N/A
Recruiting NCT02964195 - Efficacy of Rifaximin in Treatment of Cirrhotic Gastroesophageal Variceal Bleeding N/A
Completed NCT02965209 - European Novel Motorized Spiral Endoscopy Trial N/A
Completed NCT01872286 - Comparison of the Frequency-altering AKE-1 Capsule and Pillcam SB2 N/A
Completed NCT02349490 - Seraseal for Endoscopic Hemostasis Phase 4
Withdrawn NCT01005147 - Effect of Tranexamic Acid in Upper Gastrointestinal Bleeding N/A
Completed NCT00570973 - Band Ligation Versus Transjugular Intrahepatic Portosystemic Stent Shunt (TIPS) in Cirrhotics With Recurrent Variceal Bleeding Non Responding to Medical Therapy Phase 4
Completed NCT00450164 - Secondary Prophylaxis After Variceal Bleeding in Non-Responders Phase 4